MicroPort Scientific Corporation
MCRPF
Other OTC0.97
USD
-NaN
- -
MicroPort Scientific Corporation
MCRPF
(Other OTC)
Recent
price
0.97
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- MicroPort Scientific Corporation is a leading international medical devices company primarily engaged in the development, manufacturing, and marketing of innovative medical equipment and solutions. Its core product portfolio includes cardiovascular devices such as drug-eluting stents, transcatheter aortic valve implantation (TAVI) systems, electrophysiology and cardiac rhythm management devices, orthopedic and sports medicine products including joint replacement systems, neurovascular devices including intracranial stents and thrombectomy devices, endovascular implants, surgical robots, and diabetes and endocrinal management devices such as insulin and hormone infusion pumps. The company serves a broad range of medical needs including coronary artery disease, joint reconstruction, cardiac arrhythmias, strokes, and severe aortic valve stenosis, operating across Europe, Asia-Pacific, North America, and Latin America. Headquartered in Shanghai, China, MicroPort was founded in 1998 and has developed several flagship brands including Firehawk® drug-eluting stents and VitaFlow® TAVI systems. In the past two years, MicroPort has strategically expanded its global presence and product offerings, marked by significant milestones and new approvals. The company launched the SmartView Connect™ App Mobile in Europe and Australia, enhancing its connected cardiac care portfolio for Bluetooth-enabled devices. It recently introduced the pressure-sensing pulsed field ablation catheter, expanding its multi-energy cardiac ablation platform. The VitaFlow® TAVI system surpassed 1,000 overseas implantations, signaling strong international market penetration. MicroPort Coronary stents have surpassed 10 million global shipments and implantations. In orthopedics, the Evolution® CCK Revision Knee System and zirconium-based implants obtained new regulatory approvals, supporting expansion in joint replacement markets. Additionally, MicroPort secured CE marks for the VitaFlow Liberty® and AnchorMan® left atrial appendage closure (LAAC) systems and embarked on a pivotal study for its AltaValve™ replacement product in partnership with 4C Medical. A strategic partnership with Andhra Pradesh MedTech Zone (AMTZ) has opened access to the Indian medical device market. The company continues to improve operational efficiency through strict cost controls and focuses on streamlined growth by divesting non-core businesses while accelerating overseas market development. MicroPort operates through multiple business segments including cardiovascular, orthopedics and sports medicine, neurovascular, electrophysiology and cardiac rhythm management, endovascular, surgical robotics, and medical AI solutions. It targets hospitals, clinics, and healthcare providers worldwide, integrating advanced technology to address significant unmet clinical needs. Its subsidiaries, such as MicroPort Coronary and MicroPort NeuroScientific, further strengthen its diversified product offerings and geographic footprint. The company remains committed to research and development, with ongoing investments driving innovation in medical device technology and expanding product pipelines to sustain competitive advantage. Overall, MicroPort Scientific Corporation is a comprehensive medical device company with a diversified portfolio spanning implantable devices, interventional solutions, robotics, and digital healthcare, supported by recent product launches, regulatory approvals, and strategic partnerships that reinforce its global market leadership and growth trajectory.